Aduhelm 170 mg Injection

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Aduhelm 170 mg Injection (aducanumab) vial pack

Product Overview

Aduhelm 170 mg Injection contains aducanumab, a monoclonal antibody. Its labelling describes it as a treatment directed at amyloid beta, a protein that accumulates as plaques in the brain in Alzheimer’s disease, with the described aim of reducing those plaques.

Active ingredient
Aducanumab
Dosage form
Solution for intravenous infusion
Therapeutic class
Anti-amyloid monoclonal antibody
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with aducanumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Described for the treatment of Alzheimer’s disease
  • Described as targeting and reducing amyloid beta plaques in the brain
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Administered only by a healthcare professional as an intravenous infusion
  • Given at the interval set by the treating specialist; the course should be completed as prescribed
  • An up-to-date medical history should be shared with the doctor before treatment

Described Side Effects

Commonly described side effects include:

  • Amyloid-related imaging abnormalities (ARIA) — brain swelling or small bleeds seen on MRI, often without symptoms
  • Headache
  • Confusion, dizziness or visual changes
  • Falls
  • Infusion-related reactions

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Periodic MRI monitoring is described in the labelling before and during treatment
  • Symptoms such as headache, confusion, dizziness, nausea or visual disturbance should be reported promptly
  • Use in people taking blood thinners is described as requiring caution
  • Pregnancy or breastfeeding should be discussed with the prescriber

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling it contains aducanumab and is described as reducing amyloid beta plaques in the brain in Alzheimer’s disease. SDO Pharma has not independently verified these claims and makes no claim of regulatory approval in any market unless independently confirmed.

Its labelling describes an intravenous infusion administered by a healthcare professional, with MRI scans before and during treatment.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services